Every 10-Q that REGENXBIO Inc. (RGNX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RGNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RGNX filings page.
REGENXBIO Inc. reported Q3 2025 results. Total revenue was $29.7 million, driven by $23.6 million of license and royalty revenue and $6.1 million of service revenue. For the nine months, revenue reached $140.1 million.
The company posted a Q3 net loss of $61.9 million and a basic and diluted net loss per share of $1.20. Interest expense rose to $13.2 million in the quarter, reflecting royalty financing activity. Operating expenses were $82.1 million in Q3, led by $56.1 million in research and development and $20.3 million in general and administrative costs.
Cash, cash equivalents and marketable securities totaled $302.0 million as of September 30, 2025. Royalty monetization liabilities increased to $191.6 million, including a new 2025 Royalty Bond initially funded with $150.0 million (net proceeds $144.5 million). Deferred revenue rose to $34.4 million current and non-current combined, aligned with recent collaboration activity and the new presentation separating service revenue. Shares outstanding were 50,623,086 as of October 31, 2025.